All posts by: Michael Zand

About Michael Zand

“Good” Gut Bacteria Linked to Melanoma Immunotherapy Response – Genetic Engineering & Biotechnology News (press release)

Continue reading

2017-10-06 NEWS

Genetic Engineering & Biotechnology News (press release)

“Good” Gut Bacteria Linked to Melanoma Immunotherapy Response
Genetic Engineering & Biotechnology News (press release)
Scientists have uncovered a link between an individual’s gut bacteria and their response to anticancer immune checkpoint inhibitor therapy (ICT). A team of researchers at the Harold C. Simmons Comprehensive Cancer Center in Texas carried out what they …

and more »

Continue reading

2017-10-06 NEWS

Genetic Engineering & Biotechnology News (press release)

“Good” Gut Bacteria Linked to Melanoma Immunotherapy Response
Genetic Engineering & Biotechnology News (press release)
Scientists have uncovered a link between an individual’s gut bacteria and their response to anticancer immune checkpoint inhibitor therapy (ICT). A team of researchers at the Harold C. Simmons Comprehensive Cancer Center in Texas carried out what they …

and more »

Continue reading

2017-10-06 NEWS

Virus-specific T cells attack infections after hematopoietic stem cell transplantation
Healio
An “off-the-shelf” approach using virus-directed virus-specific T cells safely and effectively treated patients with severe viral infections following allogeneic hematopoietic stem cell transplantation, according to phase 2 trial results published in

Continue reading

2017-10-06 NEWS

Human Gut Microbiome Linked with Response to Cancer Immunotherapy
Genetic Engineering & Biotechnology News
Scientists have identified a link between an individual’s gut bacteria and their likely response to anticancer immune checkpoint inhibitor therapy (ICT). A team of researchers at the Harold C. Simmons Comprehensive Cancer Center in Texas carried out

and more »

Continue reading

2017-10-06 NEWS

Rare Disease Report

Gene Therapy for HD Gets FDA Orphan Designation
Rare Disease Report
uniQure N.V., the company that developed the first-ever approved gene therapy (for familial chylomicronemia syndrome), announced that the U.S. Food and Drug Administration (FDA) has now granted an Orphan Drug Designation for its gene therapy …
uniQure Announces FDA Orphan Drug Designation for AMT-130 in Huntington’s disease~ First Investigational GeneMarkets Insider
uniQure (QURE) Granted FDA Orphan Drug Designation for AMT-130 in Huntington’s DiseaseStreetInsider.com

all 5 news articles »

Continue reading

2017-10-06 NEWS

Technology Networks

CRISPR-Gold Fixes Duchenne Muscular Dystrophy Mutation in Mice
Technology Networks
CRISPR–Gold is composed of 15 nanometer gold nanoparticles that are conjugated to thiol-modified oligonucleotides (DNA-Thiol), which are hybridized with single-stranded donor DNA and subsequently complexed with Cas9 and encapsulated by a polymer …